Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613317 | 0.85 | ACE (0.60) | MEN1KMT2ARIPK1ACETRPM8 | |
| SCHEMBL25142645 | 0.85 | GHSR (0.47) | ACETRPM8 | |
| SCHEMBL18701726 | 0.83 | TRPM8 (0.50) | MEN1KMT2ARIPK1ACETRPM8 | |
| SCHEMBL18701727 | 0.83 | TRPM8 (0.50) | MEN1KMT2ARIPK1ACETRPM8 | |
| SCHEMBL19953516 | 0.82 | F11 (0.53) | ACETRPV1MTNR1BDRD1 | |
| SCHEMBL19960667 | 0.82 | F11 (0.53) | ACETRPV1MTNR1BDRD1 | |
| SCHEMBL17058892 | 0.82 | ACE (0.50) | MEN1KMT2ARIPK1ACETRPM8 | |
| SCHEMBL7146356 | 0.80 | GHSR (0.43) | ACETRPM8MTNR1B | |
| SCHEMBL3609162 | 0.80 | KMT2A (0.47) | MEN1KMT2ALMNA | |
| SCHEMBL3605488 | 0.80 | MEN1 (0.47) | MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | MEN1 4401/4885KMT2A 343/4885RIPK1 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.